BioNTech SE (0A3M.L)
| Previous close | 162.58 |
| Open | 164.46 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 162.68 - 165.29 |
| 52-week range | 95.50 - 195.00 |
| Volume | |
| Avg. volume | 24,837 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.25 |
| PE ratio (TTM) | 0.03 |
| EPS (TTM) | 52.02 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireBioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studi
GlobeNewswireBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a large majority of the shareholders. “The past few years marked a leap in competence for BioNTech,” said He
Simply Wall St.We Discuss Why BioNTech SE's (NASDAQ:BNTX) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Key Insights BioNTech will host its Annual General Meeting on 17th of May CEO Ugur Sahin's total compensation includes...
